Boundless Bio Inc (BOLD): Operating Sales Margin

Symbol and logo of brand Boundless Bio, Inc. (BOLD)

Boundless Bio, Inc. (BOLD) operates a business that is not subject to seasonality or market cycles, as demand is driven by medical necessity. However, early-stage trials and capital expenditures create significant financial risks. The operating profit margin demonstrates current efficiency, where the parameter value reaches 0.00. Boundless Bio, Inc. (BOLD) is considered a pioneer in extrachromosomal DNA therapy, having earned deep trust from the scientific community through innovative methods for combating aggressive tumors.

BOLD: Boundless Bio Profitability of Operations 03/29/2024 - 11/19/2026

Analytical breakdowns for Boundless Bio, Inc.

- price and consensus price forecast:
Initial company analysis:Boundless Bio, Inc, BOLD
Finished products of boundlessbio.com

Operating margin measures cost management efficiency, reflecting the share of profit from core operations before accounting for financial expenses and taxes. By analyzing the operating profit spread, an investor assesses the ability of Boundless Bio, Inc. (BOLD) to monetize the development of inhibitors for oncology therapy, where future profitability growth depends directly on drug approvals and subsequent insurance fund payouts.

Key competitors

Operating Sales Margin TEM|QGEN - Operating Profitability Margin|Operating Margin IONS|RGEN - Operating Return on Sales|Operating Profitability Avidity RNA|Operating Margin CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operating Margin|Ultragenyx Pharma (RARE) - Operating Sales Margin|beamtx.com (BEAM) - Operating Profitability|SRPT: Operating Profit Ratio|Operating Sales Margin TWST|TXG - Operating Profitability Margin|Operating Margin NTLA|Profitability of Operations Stoke Therapeutics|Operating Profitability BioLife Solutions BLFS|Wave Life Sciences (WVE) - Operating Return on Sales|Maze Therapeutics, Inc. - Operating Margin|Profitability of Operations Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Operating Profitability|TSHA: Operating Profit Ratio|Operating Profitability uniQure Pharma|MGTX - Operating Profitability Margin|Operating Margin RGNX|Operating Profitability SLDB (Solid Biosciences)|Ocugen Corp - Operating Sales Margin|PACB: Return on Sales by Operating Profit|benitec.com - Operating Margin|DSGN - Operating Margin|RCKT: Operating Margin|FDMT (4D Molecular Therapeutics Inc) - Operating Profitability|Operating Sales Margin LXEO|Operating Profitability KRRO|Operating Margin EDIT|SLN - Operating Return on Sales|Operating Margin PRQR (ProQR)|CDXS - Operating Sales Margin|Sangamo Therapeutics Inc. - Operating Margin|NAUT - Operating Margin|MGX: Operating Margin|Operating Sales Margin Precision BioSciences, Inc.|GBIO (Generation Bio) - Operating Margin|Operating Sales Margin Exicure (XCUR)|Operating Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operating Profit Rate|Mustang Bio, Inc. - Operating Sales Margin|RNAZ - Operating Sales Margin|BNGO: Operating Sales Margin|APDN (Applied DNA Sciences Inc) - Return on Sales by Operating Profit|BLUE (Bluebird Bio) - Operating Sales Margin|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability